Frances Unger, William Patterson, Lead Gordon Ellis, Lead v. Amedisys Inc.

401 F.3d 316, 2005 U.S. App. LEXIS 2778, 2005 WL 375684
CourtCourt of Appeals for the Fifth Circuit
DecidedFebruary 17, 2005
Docket03-30965
StatusPublished
Cited by199 cases

This text of 401 F.3d 316 (Frances Unger, William Patterson, Lead Gordon Ellis, Lead v. Amedisys Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Frances Unger, William Patterson, Lead Gordon Ellis, Lead v. Amedisys Inc., 401 F.3d 316, 2005 U.S. App. LEXIS 2778, 2005 WL 375684 (5th Cir. 2005).

Opinions

EDITH H. JONES, Circuit Judge:

This case, on review pursuant to Fed. Rule Civ. PROC. 23(f), implicates the standards and procedures used by district courts when considering certification of securities class actions dependent on the “fraud on the market” theory. See Basic, Inc. v. Levinson, 485 U.S. 224, 108 S.Ct. 978, 99 L.Ed.2d 194 (1988). Like our brethren in the Third, Fourth, Seventh and Ninth Circuits, we hold that a careful certification inquiry is required and findings must be made based on adequate admissible evidence to justify class certification. Because the district court erroneously applied too lax a standard of proof to the plaintiffs’ fraud-on-the-market allegations, we must vacate the class certification and remand.

BACKGROUND

Amedisys provides home health care, nursing, home infusion therapy, and ambulatory surgery services. The company’s stock is traded on the NASDAQ Over The Counter Bulletin Board (“OTCBB”). Approximately ninety percent of Amedisys’s revenue comes from Medicare. This case stems from the conduct of Amedisys and its directors in reporting profits based on new Medicare procedures.

Beginning October 1, 2000, Medicare implemented the Prospective Payment System (“PPS”), which altered the way Medicare compensated home health care companies. Under PPS, Medicare paid health care companies like Amedisys a portion of their fees in advance, based on forward-looking estimates of the cost of services. After the company provided the service, the remainder of the fee was paid; alternatively, if the initial payment proved too high, the company had to reimburse Medicare the difference. To comply with the new PPS procedures, Amedisys purchased and implemented new computer software.

Plaintiffs allege that Amedisys willfully manipulated the PPS program to inflate the estimated costs for certain health services; that it thereby artificially fueled company earnings; and, ultimately, that Amedisys’s actions wrongfully enhanced its stock price. On June 13, 2001, Amedi-sys issued a curative statement, conceding that it had overstated revenues, but maintaining that the overstatements were inadvertently caused by the new software used with the PPS program. The stock price fell.

On August 21, 2001, Frances Unger filed suit against Amedisys, alleging violations [320]*320of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. As is often the case, plaintiffs’ lawyers solicited potential class members over the Internet and through newspaper advertisements. Several other suits were consolidated with Un-ger’s ahd five individuals were chosen as lead plaintiffs. Class certification was requested for “all persons and entities who purchased the common stock of Amedisys, Inc. between November 15, 2000 through [sic] June 13, 2001.” Discovery occurred to ascertain the qualifications of the proposed class representatives. At a hearing, the district court evaluated this evidence and the plaintiffs’ sketchy evidence in support of the fraud-on-the-market basis for their presumed reliance on Amedisys’s misrepresentations. The district court certified the- class under Rule 23(b)(3).

The Amedisys defendants timely sought, and this court granted, an interlocutory appeal raising two issues embodied in the class certification: the adequacy of the lead plaintiffs’ qualifications and the sufficiency of plaintiffs’ evidence to support the fraud on the market presumption.

DISCUSSION

The class certification determination rests within the sound discretion of the'trial court. Gulf Oil Co. v. Bernard, 452 U.S. 89, 100, 101 S.Ct. 2193, 2200, 68 L.Ed.2d 693 (1981). That discretion, however, must be exercised within the constraints of Rule 23. Id. A district court that premises its legal analysis on an erroneous understanding of the governing law has abused its discretion. U.S. v. Insaulgarat, 378 F.3d 456, 464 (5th Cir.2004); U.S. v. Mann, 161 F.3d 840, 860 (5th Cir.1998).

Rule 23 requires the claims of a proposed class to meet several requirements before the class can be certified. The party seeking certification bears the burden of establishing that all requirements of Rule 23 have been satisfied. Berger v. Compaq Computer Corp., 257 F.3d 475, 479-80 (5th Cir.2001). First, the district court must find what has been termed numerosity, commonality, typicality, and representativeness.1 For class actions seeking money damages, like this one, the district court must make additional findings of predominance and superiority. Rule 23(b)(3). The predominance element requires a finding that common issues of law or fact “predominate over any questions affecting only individual members.” Id. This requirement, although reminiscent of the commonality requirement of Rule 23(a), is “far more demanding” because it “tests whether proposed classes are sufficiently cohesive to warrant adjudication by representation.” Amchem Prods., Inc. v. Windsor, 521 U.S. 591, 623-24, 117 S.Ct. 2231, 2249-50, 138 L.Ed.2d 689 (1997). Finally, a class action must afford the superior means to achieve “fair and efficient adjudication of the controversy.” Rule 23(b)(3).

Recognizing the important due process concerns of both plaintiffs and defendants inherent in the certification decision, the Supreme Court requires district courts to conduct a rigorous analysis of Rule 23 prerequisites. Gen’l Tel. Co. v. [321]*321Falcon, 457 U.S. 147, 161, 102 S.Ct. 2364, 2372, 72 L.Ed.2d 740 (1982). District courts are required to take a “close look” at the parties’ claims and evidence in making its Rule 23 decision. Amchem, 521 U.S. at 615, 117 S.Ct. at 2246. Class certification hearings should not be mini-trials on the merits of the class or individual claims. Eisen v. Carlisle & Jacquelin, 417 U.S. 156, 177-78, 94 S.Ct. 2140, 2152-53, 40 L.Ed.2d 732 (1974). At the same time, however, “[g]oing beyond the pleadings is necessary, as a court must understand the claims, defenses, relevant facts, and applicable substantive law in order to make a meaningful determination of the certification issues.” Castano v. Am. Tobacco Co., 84 F.3d 734, 744 (5th Cir.1996). To assist the court in this process it may sanction controlled discovery at the certification stage. See Fed.R.Civ.P. 23 Advisory Committee’s Note to 2003 amendments. The plain text of Rule 23 requires the court to “find,” not merely assume, the facts favoring class certification. Rule 23(b)(3).

Appellants first challenge the qualifications of the class representatives under Rule 23(a)(4).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Irma Allen v. Ollies Bargain Outlet Inc
37 F.4th 890 (Third Circuit, 2022)
Brian Lyngaas v. Curaden AG
Sixth Circuit, 2021
Prantil v. Arkema
986 F.3d 570 (Fifth Circuit, 2021)
Heriberto Chavez v. Plan Benefit Services
957 F.3d 542 (Fifth Circuit, 2020)
Richard Tredinnick v. Jackson National Life
954 F.3d 240 (Fifth Circuit, 2020)
State of Texas v. USA
945 F.3d 355 (Fifth Circuit, 2019)
Marlyn Sali v. Corona Regional Medical Center
889 F.3d 623 (Ninth Circuit, 2018)
Waggoner v. Barclays PLC
Second Circuit, 2017
Izzio v. Century Golf Partners Management, L.P.
670 F. App'x 348 (Fifth Circuit, 2016)
Strougo v. Barclays PLC
312 F.R.D. 307 (S.D. New York, 2016)
Byer Clinic and Chiropractic, Ltd. v. Kapraun
2016 IL App (1st) 143733 (Appellate Court of Illinois, 2016)
Carpenters Pension Trust Fund v. Barclays PLC
310 F.R.D. 69 (S.D. New York, 2015)
Quinton Brown v. Nucor Corporation
785 F.3d 895 (Fourth Circuit, 2015)
Vinh Nguyen v. Radient Pharmaceuticals Corp.
287 F.R.D. 563 (C.D. California, 2012)
Ahmad v. Old Republic National Title Insurance
690 F.3d 698 (Fifth Circuit, 2012)
In Re RAIL FREIGHT FUEL SURCHARGE ANTITRUST LITIGATION
287 F.R.D. 1 (District of Columbia, 2012)
In Re Zurn Pex Plumbing Products Liability
644 F.3d 604 (Eighth Circuit, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
401 F.3d 316, 2005 U.S. App. LEXIS 2778, 2005 WL 375684, Counsel Stack Legal Research, https://law.counselstack.com/opinion/frances-unger-william-patterson-lead-gordon-ellis-lead-v-amedisys-inc-ca5-2005.